|
|
|
|
|
Research Progress on Immunoregulation of Chemotherapeutic Agents |
| LIU Zhenghao, YANG Chunguang, HU Zhiquan |
| Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China |
|
|
|
|
Abstract Chemotherapeutic drugs are the mainstay of treatment on mid-advanced tumors. In recent years, more and more studies have shown that chemotherapeutic drugs also have immunomodulatory effects. Some chemotherapeutic drugs can enhance anti-tumor immunity by inducing tumor cell immunogenic cell death or performing “immunogenic modulation”. In addition, chemotherapeutic drugs can also act on immune cells and even the intestinal flora. A number of clinical trials of chemotherapy combined with immune checkpoint inhibitors are currently underway. This article focuses on the immunomodulatory effect of chemotherapeu tic drugs, as well as the potential of chemotherapy combined with ICI on cancer, to provide guidance for the clinical application of chemotherapeutic drugs.
|
| Keywords
Antineoplastic; Chemotherapy; Immunomodulation; Gastrointestinal microbiome; Immune checkpoint inhibitors
|
|
|
|
Issue Date: 11 January 2022
|
|
[1] Schirrmacher V. From chemotherapy to biological therapy: A
review of novel concepts to reduce the side effects of systemic
cancer treatment[J]. Int J Oncol, 2019, 54(2): 407-419.
[2] Mannie MD, DeOca KB, Bastian AG, et al. Tolerogenic vaccines:
Targeting the antigenic and cytokine niches of FOXP3+ regulatory
T cells[J]. Cell Immunol, 2020, 355: 104173.
[3] Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for
the definition, detection and interpretation of immunogenic cell
death[J]. J Immunother Cancer, 2019, 8(1): e000337.
[4] Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with
chemotherapy in the era of immune checkpoint inhibitors[J]. Nat
Rev Clin Oncol, 2020, 17(12): 725-741.
[5] Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in
immune-oncology[J]. Nat Rev Cancer, 2019, 19(3): 151-161.
[6] Sabbatino F, Liguori L, Polcaro G, et al. Role of Human
Leukocyte Antigen System as A Predictive Biomarker for
Checkpoint-Based Immunotherapy in Cancer Patients[J]. Int J
Mol Sci, 2020, 21(19): 7295.
[7] Gravett AM, Trautwein N, Stevanovi? S, et al. Gemcitabine alters
the proteasome composition and immunopeptidome of tumour
cells[J]. Oncoimmunology, 2018, 7(6): e1438107.
[8] Galaine J, Turco C, Vauchy C, et al. CD4 T cells target colorectal
cancer antigens upregulated by oxaliplatin[J]. Int J Cancer, 2019,
145(11): 3112-3125.
[9] Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms
of cell death: recommendations of the Nomenclature Committee
on Cell Death 2018[J]. Cell Death Differ, 2018, 25(3): 486-541.
[10] Ou W, Nam KS, Park DH, et al. Artificial Nanoscale Erythrocytes
from Clinically Relevant Compounds for Enhancing Cancer
Immunotherapy[J]. Nanomicro Lett, 2020, 12(1): 90.
[11] Huang FY, Wang JY, Dai SZ, et al. A recombinant oncolytic
Newcastle virus expressing MIP-3α promotes systemic antitumor
immunity[J]. J Immunother Cancer, 2020, 8(2): e000330.
[12] Huang X, Tang T, Zhang G, et al. Genomic investigation of
co-targeting tumor immune microenvironment and immune
checkpoints in pan-cancer immunotherapy[J]. NPJ Precis Oncol,
2020, 4(1): 29.
[13] Xu P, Liang F. Nanomaterial-Based Tumor Photothermal
Immunotherapy[J]. Int J Nanomedicine, 2020, 15: 9159-9180.
[14] Bhushan J, Radke JB, Perng YC, et al. ISG15 Connects Autophagy
and IFN-gamma-Dependent Control of Toxoplasma gondii
Infection in Human Cells[J]. mBio, 2020, 11(5): e00852-20.
[15] Miar A, Arnaiz E, Bridges E, et al. Hypoxia Induces
Transcriptional and Translational Downregulation of the Type I
IFN Pathway in Multiple Cancer Cell Types[J]. Cancer Res, 2020,
80(23): 5245-5256.
[16] Mackenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance
of micronuclei links genome instability to innate immunity[J].
Nature, 2017, 548(7668): 461-465.
[17] Wu C, Du X, Tang L, et al. Schistosoma japonicum SjE16.7
Protein Promotes Tumor Development via the Receptor for
Advanced Glycation End Products (RAGE)[J]. Front Immunol,
2020, 11: 1767.
[18] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor
4-dependent contribution of the immune system to anticancer
chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9):
1050-1059.
[19] Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced
antitumor immunity requires formyl peptide receptor 1[J].
Science, 2015, 350(6263): 972-978.
[20] Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2
purinergic signalling in the tumour microenvironment[J]. Nat Rev
Cancer, 2018, 18(10): 601-618.
[21] Yang W, Deng H, Zhu S, et al. Size-transformable antigenpresenting
cell-mimicking nanovesicles potentiate effective cancer
immunotherapy[J]. Sci Adv, 2020, 6(50): eabd1631.
[22] Taniguchi K, Karin M. NF-κB, inflammation, immunity and
cancer: coming of age[J]. Nat Rev Immunol, 2018, 18(5): 309-324.
[23] Wu D, Zhao Z, Kim J, et al. Gemcitabine and doxorubicin in
immunostimulatory monophosphoryl lipid A liposomes for
treating breast cancer[J]. Bioeng Transl Med, 2021, 6(1): e10188.
[24] Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell
death in non-small cell lung cancer[J]. Nat Commun, 2019, 10(1):
1486.
[25] Bezu L, Sauvat A, Humeau J, et al. eIF2a phosphorylation is
pathognomonic for immunogenic cell death[J]. Cell Death Differ,
2018, 25(8): 1375-1393.
[26] Humeau J, Sauvat A, Cerrato G, et al. Inhibition of transcription
by dactinomycin reveals a new characteristic of immunogenic cell
stress[J]. EMBO Mol Med, 2020, 12(5): e11622.
[27] Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced
immunogenic modulation of tumor cells enhances killing by
cytotoxic T lymphocytes and is distinct from immunogenic cell
death[J]. Int J Cancer, 2013, 133(3): 624-636.
[28] Ardiani A, Farsaci B, Rogers CJ, et al. Combination Therapy
with a Second-Generation Androgen Receptor Antagonist and a
Metastasis Vaccine Improves Survival in a Spontaneous Prostate
Cancer Model[J]. Clin Cancer Res, 2013, 19(22): 6205-6218.
[29] Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with
chemotherapy in the era of immune checkpoint inhibitors[J]. Nat
Rev Clin Oncol, 2020, 17(12): 725-741.
[30] Takeuchi S, Baghdadi M, Tsuchikawa T, et al. Chemotherapy-
Derived Inflammatory Responses Accelerate the Formation
o f I m m u n o s u p p r e s s i v e M y e l o i d C e l l s i n t h e Ti s s u e
Microenvironment of Human Pancreatic Cancer[J]. Cancer Res,
2015, 75(13): 2629-2640.
[31] Wesolowski R, Duggan MC, Stiff A, et al. Circulating myeloidderived
suppressor cells increase in patients undergoing neoadjuvant
chemotherapy for breast cancer[J]. Cancer Immunol,
Immunother, 2017, 66(11): 1437-1447.
[32] Ahmad I, Valverde A, Naqvi RA, et al Long Non-coding RNAs
RN7SK and GAS5 Regulate Macrophage Polarization and Innate
Immune Responses[J]. Front Immunol, 2020, 11: 604981.
[33] Nakamura K, Smyth MJ. Myeloid immunosuppression and
immune checkpoints in the tumor microenvironment[J]. Cell Mol
Immunol, 2020, 17(1): 1-12.
[34] McDonnell AM, Lesterhuis WJ, Khong A, et al. Tumor-infiltrating
dendritic cells exhibit defective cross-presentation of tumor
antigens, but is reversed by chemotherapy[J]. Eur J Immunol,
2015, 45(1): 49-59.
[35] 罗佳, 金锋. 肠道菌群影响宿主行为的研究进展[J]. 科学通报,
2014, 59(22): 2169-2190. [Luo J, Jin F. Research progress on the
influence of intestinal flora on host behavior[J]. Ke Xue Tong
Bao, 2014, 59(22): 2169-2190.]
[36] Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation
impinges on gut microbial markers defining novel biomarkers for
serrated colorectal cancer effective therapies[J]. J Exp Clin Cancer
Res, 2020, 39(1): 285.
[37] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome
modulates response to anti-PD-1 immunotherapy in melanoma
patients[J]. Science, 2018, 359(6371): 97-103.
[38] Yang Y, Luo M, Zhang K, et al. Nedd4 ubiquitylates VDAC2/3
to suppress erastin-induced ferroptosis in melanoma[J]. Nat
Commun, 2020, 11(1): 433.
[39] Weber J. Immune Checkpoint Proteins: A New Therapeutic
Paradigm for Cancer Preclinical Background: CTLA-4 and PD-1
Blockade[J]. Semin Oncol, 2010, 37(5): 430-439.
[40] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and
Immune Correlates of Anti-PD-1 Antibody in Cancer[J]. N Engl J
Med, 2012, 366(26): 2443-2454.
[41] Leduc C, Adam J, Louvet E, et al. TPF induction chemotherapy
increases PD-L1 expression in tumour cells and immune cells in
head and neck squamous cell carcinoma[J]. ESMO Open, 2018,
3(1): e000257.
[42] Gu Z, Wang Q, Shi Y, et al. Nanotechnology-mediated
immunochemotherapy combined with docetaxel and PD-L1
antibody increase therapeutic effects and decrease systemic
toxicity[J]. J Control Release, 2018, 286: 369-380.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
